Table 3.
Ongoing trials evaluating activity and efficacy of different immunotherapy strategies in PC (Clinicaltrials.gov last accessed 10 June 2021).
| Target | Tumor | Setting | Treatment Arms | Phase | Primary Outcome | N of Patients | clinicaltrial.gov Identifier |
|---|---|---|---|---|---|---|---|
| PD-L1 TGF-βRII |
PC | Advanced, pretreated | gemcitabine + nab-paclitaxel + SHR-1701 | Ib/II | ORR RP2D |
54 | NCT04624217 |
| PD-L1 CTLA-4 |
PC | Locally advanced | minimally invasive surgical microwave ablation + durvalumab + tremelimumab + gemcitabine | II | PFS | 20 | NCT04156087 |
| PD-1 CTLA-4 |
PC | Metastatic | nivolumab + ipilimumab + radiation | II | ORR | 30 | NCT04361162 |
| PD-1 | PC | Metastatic | (1) FOLFIRINOX (2) FOLFIRINOX + Anti-PD-1 antibody |
III | OS | 110 | NCT03977272 |
| PD-1 | PC | Locally advanced | (1) FOLFIRINOX (2) FOLFIRINOX + anti-PD-1 antibody |
III | PFS | 830 | NCT03983057 |
| PD-1 | PC | Metastatic, untreated | gemcitabine + S-1 + nivolumab | II | ORR | 38 | NCT04377048 |
| CSF1R PD-1 |
PC | Advanced, pretreated | (1) gemcitabine/nab-paclitaxel or 5-FU/leucovorin/irinotecan liposome (2) cabiralizumab + nivolumab (3) gemcitabine + nab-paclitaxel + cabiralizumab + nivolumab (4) cabiralizumab + nivolumab + FOLFOX |
II | PFS | 179 | NCT03336216 |
| PD-1 | PC | Metastatic | (1) FOLFIRINOX/mFOLFIRINOX + anti-PD-1 (2) FOLFIRINOX/mFOLFIRINOX |
III | OS | 110 | NCT03977272 |
| PD-L1 CTLA4 |
PC | Advanced | (1) 2nd line PD-L1/CTLA4 inhibitor(2) 1st line PD-L1/CTLA4 inhibitor + gemcitabine/nab-paclitaxel (3) 1st line PD-L1/CTLA4 inhibitor + FOLFIRINOX |
I/II | ORR | 60 | NCT04324307 |
| CXCR4 PD-1 |
PC | Metastatic pretreated | plerixafor + cemiplimab | II | ORR | 21 | NCT04177810 |
| PD-L1 ICOS |
AST | Advanced, pretreated | (1) KY1044 (2) KY1044 + atezolizumab |
I/II | ORR Safety |
412 | NCT03829501 |
| ETBR PD-1 |
AST | Advanced pretreated | ENB-003 + pembrolizumab | I/II | ORR Safety |
130 | NCT04205227 |
| PD-1 | AST | Advanced, pretreated | (1) pembrolizumab + lenvatinib (2) lenvatinib | II | ORR Safety |
760 | NCT03797326 |
| CD11b PD-1 |
AST | Advanced | (1) GB1275 GB1275 + anti PD-1 |
I/II | ORR Safety |
242 | NCT04060342 |
AST: advanced solid tumor; PC: pancreatic cancer; N: number; PFS: progression-free survival; OS: overall survival; ORR: objective response rate; PD-1: programmed death-1; PD-L1: programmed death ligand 1; PD: progressive disease; mFOLFIRINOX: modified FOLFIRINOX; RP2D: recommended phase 2 dose; CTLA-4: cytotoxic T-lymphocyte antigen 4; TGF-βRII: transforming growth factor-beta receptor II; CXCR4: C-X-C motif chemokine receptor 4; CSF1R: colony stimulating factor 1 receptor; ETBR: endothelin B receptor.